Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-024194-39
    Sponsor's Protocol Code Number:BO21005
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2011-09-02
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2010-024194-39
    A.3Full title of the trial
    A Phase III, Multicenter, Open-Label, Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination with CHOP (G-CHOP) Versus Rituximab and CHOP (RCHOP)in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma(DLBCL)
    Studio di fase III, multicentrico, in aperto, randomizzato per confrontare l’efficacia di GA101 (RO5072759) in combinazione a CHOP (G-CHOP), rispetto a Rituximab e CHOP, (R CHOP) in pazienti con Linfoma Diffuso a Grandi Cellule B (DLBCL) CD20-positivo non trattati in precedenza
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of RO5072759 (GA101) in Combination with CHOP Versus Mabthera/Rituxan (Rituximab) with CHOP in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma
    Studio di RO5072759 (GA101) in combinazione con chemioterapia CHOP, rispetto a Mabthera/Rituxan (Rituximab) con CHOP, in pazienti con Linfoma Diffuso a Grandi Cellule B (DLBCL) CD20-positivo
    A.3.2Name or abbreviated title of the trial where available
    GOYA
    GOYA
    A.4.1Sponsor's protocol code numberBO21005
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01287741
    A.5.4Other Identifiers
    Name:NDNumber:ND
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. Hoffmann - La Roche Ltd.
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffman La Roche AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF. Hoffmann - La Roche Ltd.
    B.5.2Functional name of contact pointTrial Information Support Line-TILS
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number.
    B.5.5Fax number.
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRO5072759
    D.3.2Product code GA101
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNobinutuzimab
    D.3.9.1CAS number 949142-50-1
    D.3.9.2Current sponsor codeRO5072759/F06
    D.3.9.3Other descriptive nameGA101
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeanticorpo monoclonale umanizzato e glicoingenierizzato
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name MabThera
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration Ltd
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRITUXIMAB
    D.3.9.1CAS number 174722-31-7
    D.3.9.2Current sponsor codeRo 045-2294/V01
    D.3.9.3Other descriptive nameMabThera
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeAnticorpo monoclonale murino/umano
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name MabThera
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration Ltd
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRITUXIMAB
    D.3.9.1CAS number 174722-31-7
    D.3.9.2Current sponsor codeRo 045-2294/V02
    D.3.9.3Other descriptive nameMabThera
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeAnticorpo monoclonale murino/umano
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    PREVIOUSLY UNTREATED PATIENTS WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA DLBCL)
    Pazienti affetti da Linfoma Diffuso a Grandi Cellule B (DLBCL) CD20-positivo non trattati in precedenza
    E.1.1.1Medical condition in easily understood language
    CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
    Linfoma Diffuso a Grandi Cellule B (DLBCL) CD20-positivo
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.0
    E.1.2Level HLT
    E.1.2Classification code 10012819
    E.1.2Term Diffuse large B-cell lymphomas
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.0
    E.1.2Level SOC
    E.1.2Classification code 10005329
    E.1.2Term Blood and lymphatic system disorders
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.0
    E.1.2Level PT
    E.1.2Classification code 10012818
    E.1.2Term Diffuse large B-cell lymphoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.0
    E.1.2Level SOC
    E.1.2Classification code 10029104
    E.1.2Term Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to demonstrate superiority in progression-free survival (PFS) with GA101 plus chemotherapy (G-CHOP) compared with rituximab plus chemotherapy (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL), based on investigator-assessed PFS.
    Dimostrare la superiorita' in termini di sopravvivenza libera da progressione (progression free survival, PFS), sulla base della valutazione dello sperimentatore, del trattamento GA101 piu' chemioterapia CHOP (G-CHOP) rispetto al trattamento rituximab piu' chemioterapia CHOP (R CHOP) in pazienti affetti da linfoma diffuso a grandi cellule B CD20-positivo non precedentemente trattati.
    E.2.2Secondary objectives of the trial
    • OS • ORR and CRR after the end of treatment between the two arms, as assessed by the investigator • PFS as assessed by the IRC • overall response rate and CR rate based on the IRC assessment after the end of treatment • event-free survival (EFS), as assessed by the investigator • disease-free survival (DFS), duration of response (DOR)and time to next lymphoma treatment.The DFS and DOR will be based on the investigator’s assessment. • safety and tolerability of GA101 in combination with CHOP • quality-of-life measures
    • sopravvivenza globale (OS) • sopravvivenza libera da eventi (EFS) • risposta globale (CR o PR) alla fine del trattamento alla fine del tratt.in base alla valutazione dello sperim.; • risposta completa (CR) alla fine del tratt. in base alla valutazione dello sperim.; • sopravvivenza libera da progressione (PFS) in base alla valutazione dell’IRC; • risposta globale (CR o PR) alla fine del trattamento in base alla valutazione dell’IRC; • risposta completa (CR) alla fine del trattamento in base alla valutazione dell’IRC; • sopravvivenza libera da malattia (DFS); • durata della risposta (DOR); • tempo ad un nuovo trattamento per il linfoma (TTNLT); • utilizzo di risorse mediche; sicurezza e tollerabilità di GA101 in combinazione a CHOP; • misure della qualità della vita
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    PHARMACOGENETIC:
    Vers:1
    Date:2011/01/06
    Title:SAMPLE STORAGE FOR ROCHE CLINICAL REPOSITORY (RCR)
    Objectives:To learn more about:
    - new information about the development of lymphoma and related diseases;
    - how GA101 works in the treatment of lymphoma and related diseases;
    - new information about the predictors of lymphoma progression.

    FARMACOGENETICA:
    Vers:1
    Data:2011/01/06
    Titolo:RACCOLTA DI CAMPIONI PER L’ARCHIVIO CLINICO DI ROCHE(Roche Clinical Repository - RCR)
    Obiettivi:Acquisire maggiori informazioni sui seguenti aspetti:
    - nuove informazioni sullo sviluppo dei linfomi e le malattie ad essi correlate
    - meccanismo d’azione di GA101 nel trattamento dei linfomi e delle malattie correlate
    - nuove informazioni sui fattori predittivi di progressione dei linfomi

    E.3Principal inclusion criteria
    Written informed consent • Previously untreated CD20-positive DLBCL histologically documented using the following: The pathology report must be available for review and a tissue block sent for retrospective central confirmation. Formalin-fixed paraffin-embedded tissue blocks are preferred; however, in countries using a different fixative, any tissue block available will be accepted and notation of the type of fixative included. If a tissue block is not available, 15 unstained slides will be accepted. The optional RCR sample and required exploratory biomarker samples will be obtained from the same tissue block. If central confirmation is unableto be performed on submitted material, stained slides used for diagnosis may also be requested. IPI disease risk score that is one of the following: low-intermediate, high-intermediate, or high risk (see Appendix F) Patients at low disease risk according to the IPI are eligible if they have bulky disease (one lesion ≥ 7.5 cm). • At least one bi-dimensionally measurable lesion defined as > 1.5 cm in its largest dimension on CT scan • Ability and willingness to comply with the study protocol procedures • Age ≥ 18 years • ECOG performance status of 0, 1, or 2 (see Appendix G) • LVEF ≥ 50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram • Adequate hematologic function, defined as follows: Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1.5 × 109/L Platelet count ≥ 75 × 109/L • For men who are not surgically sterile: agreement to use a barrier method of contraception during the treatment period and until ≥ 3 months after the last dose of GA101 or rituximab, or according to institutional guidelines for CHOP chemotherapy, whichever is longer, and agreement to request that their partners use an additional method of contraception, such as oral contraceptives, intrauterine device, barrier method, or spermicidal jelly • For women of reproductive potential who are not surgically sterile: agreement to use two adequate methods of contraception, such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly during the treatment period and until ≥ 12 months after the last dose of GA101 or rituximab, or according to institutional guidelines for CHOP chemotherapy, whichever is longer
    • Consenso informato scritto • Linfoma CD-20 positivo diffuso a grandi cellule B (DLBCL) non trattato in precedenza con diagnosi istologica documentata come segue: - Il referto istologico deve essere disponibile per la revisione e il blocchetto tumorale deve essere inviato per la conferma centralizzata retrospettiva. - Sono preferibili i blocchetti tumorali inclusi in paraffina e fissati con formalina; tuttavia nei paesi che utilizzano un fissativo diverso, sara' accettato qualsiasi tipo di blocchetto tumorale disponibile e dovra' essere indicato il fissativo usato. - Se il blocchetto tumorale non e' disponibile, saranno accettate 15 fettine di campione non colorate. - Il campione RCR opzionale richiesto per le analisi esplorative sui biomarcatori sara' ottenuto dallo stesso blocchetto tumorale. Se non sara' possibile effettuare la conferma centralizzata sul materiale inviato, potranno essere richieste anche fettine di tessuto colorate che sono state utilizzate per la diagnosi. • Una delle seguenti categorie di rischio IPI: basso-intermedio, alto-intermedio o alto rischio (fare riferimento all’appendice F) - I pazienti con malattia a basso rischio secondo le categorie IPI sono eleggibili in caso di malattia bulky (una lesione ≥ 7.5 cm). • Almeno una lesione misurabile bi-dimensionalmente (&gt; 1.5 cm nella dimensione maggiore in base alla TAC). • Eta' ≥ 18 anni. • ECOG performance status di 0, 1o 2 (fare riferimento all’appendice G). • Frazione di eiezione LVEF ≥ 50 %, misurata tramite MUGA o ecocardiogramma • Profilo ematologico adeguato definito come segue: - emoglobina ≥ 9 g/dL - conta assoluta dei neutrofili ≥ 1.5  109/L - conta delle piastrine ≥ 75  109/L • Uomini non chirurgicamente sterili disposti ad utilizzare un metodo contraccettivo di barriera durante il periodo di trattamento in studio e fino ad un periodo ³ 3 mesi dopo l’ultima dose di GA101 o rituximab, o in accordo alle linee guida istituzionali della chemioterapia CHOP, a seconda di quale periodo sia piu' lungo, e in accordo alla richiesta che la partner utilizzi un metodo contraccettivo addizionale, come ad esempio contraccettivi orali, dispositivi intrauterini, metodo di barriera o gel spermicida. • Donne potenzialmente fertili che non sono chirurgicamente sterili disposte ad utilizzare due metodi contraccettivi adeguati, come ad esempio contraccettivi orali, dispositivi intrauterini, o metodo di barriera in associazione a gel spermicida durante il periodo di trattamento in studio e fino ad un periodo ³ 12 a mesi dopo l’ultima dose di GA101 o rituximab, o in accordo alle linee guida istituzionali per la chemioterapia CHOP, a seconda di quale periodo sia piu' lungo.
    E.4Principal exclusion criteria
    History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products • Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines; Diagnosis of transformed lymphoma (follicular IIIB) if previously treated withradiotherapy,chemotherapy or immunotherapy • Prior therapy for DLBCL,with the exception of nodal biopsy or local irradiation • Prior treatment with cytotoxic drugs or rituximab for another condition (e.g.rheumatoid arthritis) or prior use of an anti-CD20 antibody • Prior use of any monoclonal antibody within 3 months of the start of Cycle 1 • Ongoing corticosteroid use > 30 mg/day of prednisone or equivalent Pts receiving corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks duration prior to randomization (Cycle 1, Day 1). • Primary CNS lymphoma,blastic variant of MCL,or histologic evidence of transformation to a Burkitt lymphoma,primary mediastinal DLBCL,primary effusion lymphoma and primary cutaneous DLBCL • Vaccination with live vaccines within 28 days prior to randomization • Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1 • History of other malignancy that could affect compliance with the protocol or interpretation of results Pts with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix are eligible.Pts with a malignancy that has been treated but not with curativeintent will also be excluded, unless the malignancy has been in remission without treatment for ≥ 5 years prior to enrollment. • Evidence of significant,uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results,including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months,unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm) • Recent major surgery (within 4 weeks prior to the start of Cycle 1)other than for diagnosis Any of the following abnormal laboratory values: Creatinine > 1.5 times the upper limit of normal (ULN) (unless creatinine clearance normal), or calculated creatinine clearance < 40 mL/min (using the Cockcroft–Gault formula; see Appendix H) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × the ULN Total bilirubin ≥ 1.5 × the ULN: Patients with documented Gilbert disease may be enrolled if total bilirubin is ≤ 3.0 × the ULN. International normalized ratio (INR) > 1.5 × the ULN in the absence of therapeutic anticoagulation Partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) > 1.5 × the ULN in the absence of a lupus anticoagulant • Positive test results for chronic hepatitis B infection (defined as positive HBsAg serology) A maximum of 100 patients with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing. Positive test results for hepatitis C (hepatitis C virus antibody serology testing) Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA. • Known history of HIV seropositive status • Positive results for the human T-lymphotrophic 1 virus (HTLV-1) Pregnancy or lactation • Life expectancy of < 12 months
    • Anamnesi di reaz. allergiche severe o reaz. anafilattiche ad anticorpi monoclonali umanizzati o murini.Nota sensibilita' o allergia a prodotti murini. • Controindicazione a uno qualsiasi dei singoli componenti della chemiot. CHOP,inclusa precedente assunzione di antracicline. • Diagnosi di linfoma trasformato (follicolare IIIB) se precedentemente trattato con radiot., chemiot. o immunot. • Precedente terapia per DLBCL,ad eccezione di biopsia nodale o irradiazione locale. • Precedente tratt.con farmaci citotossici o rituximab per altre condiz.(ad es.artrite reumatoide) o precedente uso di un antic. anti-CD20. • Terapia precedente a base di qualsiasi antic.monoclonale nei 3 mesi precedenti l'inizio del Ciclo 1. • Uso costante di corticosteroidi con una dose superiore a 30 mg/die di prednisone o equivalente.I pts che stanno ricevendo corticosteroidi ad una dose ≤30 mg/die di prednisone o equivalente devono ricevere una dose stabile documentata per almeno 4 sett. prima della randomizz.(Ciclo 1, giorno 1). • Linfoma primitivo del SNC,varianti blastiche di linfoma mantellare (MCL),evidenza istologica di trasformaz.in linfoma di Burkitt,linfoma DLBCL primitivo del mediastino,linfoma ad effusione primaria e linfoma cutaneo DLBCL primitivo. • Vaccinaz. con vaccini vivi meno di 28 gg. prima della randomizz. • Chemiot. o altre terapie sperim. meno di 28 gg. prima dell’inizio del Ciclo 1. • Anamnesi di altra neoplasia maligna che potrebbe compromettere l’aderenza al protocollo o l’interpretazione dei risultati.I pts con anamnesi di carcinoma cutaneo basocellulare o squamocellulare o melanoma o carcinoma in situ della cervice trattati con intento curativo saranno eleggibili.I pts con anamnesi di neoplasia maligna trattata ma non con intento curativo saranno esclusi,a meno che la neoplasia sia in remissione senza tratt.da ≥5 anni prima dell’arruolam. • Evidenza di patologie concomitanti significative e non controllate,che potrebbero compromettere l’aderenza al protocollo o l’interpretazione dei risultati,tra cui malattie cardiovascolari significative (quali cardiopatia di classe III o IV secondo la New York Heart Association,infarto del miocardio negli ultimi 6 mesi,aritmie o angina instabili) oppure malattie polmonari (tra cui malattie polmonari ostruttive e anamnesi di broncospasmo sintomatico). • Recente intervento chirurgico importante (nelle 4 sett.precedenti l’inizio del Ciclo 1),ad esclusione di intervento necessario per la diagnosi. • Presenza di una qualsiasi delle seguenti anomalie dei parametri di laboratorio: Creatinina &gt;1.5 volte il limite superiore di normalita' (UNL)(a meno che la clearance della creatinina sia normale),oppure clearance renale della creatinina calcolata con la formula di Cockcroft-Gault &lt; 40 ml/min; AST o ALT &gt; 2,5 volte il UNL; Bilirubina totale ≥ 1.5 volte il UNL.I pts con documentata malattia di Gilbert possono essere arruolati se la bilirubina totale e' ≤3.0 il UNL; INR (International Normalized Ratio) &gt; 1.5 volte il UNL in assenza di terapia anticoagulante; Tempo di PTT o tempo di aPTT &gt;1.5 volte il UNL in assenza di lupus anticoagulante; Risultati posit. ai test per l’infezione cronica da epatite B (definita come positivita' all'antigene di superficie dell'epatite B.Potranno essere inclusi massimo 100 ptscon infezione da epatite B occulta o precedente (definita come positivita' all'anticorpo del core dell'epatite B e negativita' HBsAg)se il DNA virale dell'epatite B non e' rilevabile.Questi pts dovranno essere disposti ad effettuare controlli mensili del test HBV DNA • Risultati posit. ai test per epatite C (positivita' all’antic. del virus dell’epatite C). Pts positivi per l’antic. HCV saranno eleggibili solo se l’HCV RNA e' neg. • Infezione nota da virus dell'HIV • Risultati posit.al Virus Umano T-Linfotrofico 1 (HTLV I) • Donne in gravid. o allattamento • Aspettativa di vita &lt;12 mesi
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is PFS, as determined by the investigator, defined as the time from the date of randomization until the first occurrence of disease progression, relapse, or death from any cause.
    L’endpoint primario di questo studio è la PFS valutata dallo sperimentatore, definita come il tempo dalla randomizzazione al primo evento di progressione o di recidiva o al decesso per qualsiasi causa.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The PFS, as determined by the investigator, is defined as the time from the date of randomization until the first occurrence of disease progression, relapse, or death from any cause. For patients who have not progressed, relapsed, or died at the time of analysis, PFS will be censored on the date of last disease assessment. If no tumor assessments were performed after the baseline visit, PFS will be censored at the time of randomization.
    La PFS, valutata dallo sperimentatore, è definita come il tempo dalla data di randomizzazione al primo evento di progressione della malattia, recidiva o decesso per qualsiasi causa. Per i pazienti che non sono progrediti, ricaduti o deceduti al momento dell’analisi, la PFS sarà censita il giorno dell’ultima valutazione della malattia. Se non sono disponibili valutazioni del tumore dopo la visita basale, la PFS sarà censita al giorno della randomizzazione.
    E.5.2Secondary end point(s)
    • OS • ORR and CRR after the end of treatment between the two arms, as assessed by the investigator • PFS as assessed by the IRC • overall response rate and CR rate based on the IRC assessment after the end of treatment • event-free survival (EFS), as assessed by the investigator • disease-free survival (DFS), duration of response (DOR)and time to next lymphoma treatment.The DFS and DOR will be based on the investigator’s assessment. • safety and tolerability of GA101 in combination with CHOP • quality-of-life measures
    • sopravvivenza globale (OS) • sopravvivenza libera da eventi (EFS) • risposta globale (CR o PR) alla fine del trattamento alla fine del tratt.in base alla valutazione dello sperim.; • risposta completa (CR) alla fine del tratt. in base alla valutazione dello sperim.; • sopravvivenza libera da progressione (PFS) in base alla valutazione dell’IRC; • risposta globale (CR o PR) alla fine del trattamento in base alla valutazione dell’IRC; • risposta completa (CR) alla fine del trattamento in base alla valutazione dell’IRC; • sopravvivenza libera da malattia (DFS); • durata della risposta (DOR); • tempo ad un nuovo trattamento per il linfoma (TTNLT); • utilizzo di risorse mediche; sicurezza e tollerabilità di GA101 in combinazione a CHOP; • misure della qualità della vita
    E.5.2.1Timepoint(s) of evaluation of this end point
    • OS= the time from randomization until death from any cause • EFS= defined as the time from randomization to first occurrence of progression or relapse, or initiation of a non–protocol-specified anti-lymphoma therapy or death, whichever occurs first DFS, defined as the time from the first occurrence of a documented CR until relapse, as assessed by the investigator, or death from any cause • DOR, defined as the time from the first occurrence of a documented CR or PR until relapse or progression, as assessed by the investigator, or death from any cause • TTNLT, defined as the time from randomization to the initiation of a non–protocol-specified anti-lymphoma therapy or death from any cause
    • OS=tempo dalla random.al decesso per qualsiasi causa • EFS=tempo dalla random. al 1° evento di progressione o recidiva, o all’inizio di una terapia anti-linfoma non specificata dal protocollo o al decesso a seconda di quale di questi eventi si verifichi prima • DFS=tempo dalla prima CR documentata alla recidiva, o al decesso per qualsiasi causa • DOR= tempo dalla prima CR o PR documentata alla recidiva o progressione, o al decesso per qualsiasi causa; • TTNLT=tempo dalla random.all’inizio di una terapia anti-linfoma non specificata dal protocollo o al decesso per qualsiasi causa; La sicurezza e tollerabilità di GA101 in combinazione a CHOP sa
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned20
    E.8.5The trial involves multiple Member States No
    E.8.5.1Number of sites anticipated in the EEA118
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Japan
    Korea, Democratic People's Republic of
    Korea, Republic of
    Thailand
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the last patient’s last visit and will occur approximately 6.5 years (78 months) after the first patient.
    La fine dello studio corrisponderà alla data dell’ultima visita dell’ultimo paziente incluso nello studio, prevista circa 78 mesi dopo l’arruolamento del primo paziente.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months78
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months78
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Information not present in EudraCT
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 910
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 490
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state150
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 484
    F.4.2.2In the whole clinical trial 1400
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Post study treatment is left at the Investigator's discretion.
    Il trattamento al termine dello studio è a discrezione dello sperimentatore.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation Federazione Italiana Linfomi
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2011-05-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2011-05-13
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-01-31
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:22:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA